Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
First quarter 2018 results announcement
We announced our first quarter results for the period ended 31 March 2018 on Wednesday 25 April.
Latest information
Latest press releases
- Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
- GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference
- Simon Dingemans, Chief Financial Officer, to retire from GSK
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
On Tuesday 27 March, we announced that GSK has reached an agreement with Novartis to buyout Novartis’s 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).
The press release is available here and materials from a call for investors and analysts are available below.